Magnitude of Osteoarthritis disadVantage on pEoples liveS (MOVES)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01423097
First received: August 24, 2011
Last updated: October 9, 2012
Last verified: October 2012
  Purpose

Estimate the prevalence of self-reported osteoarthritis and its characterization in adults over 45 years of age:

  • Characterization of self-reported patients with OA (socio-demographic, comorbidities, VAS for intensity of pain)
  • Characterization of OA diagnosis in patients with self-reported OA
  • Impact of self-reported OA in the working abilities, quality of life and functionality (SF-12 v2.0)
  • Characterization of treatment approaches (therapeutic and non-therapeutic) for self-reported patients with OA
  • Patient perception of impact of OA in its life and importance given to disease

Condition
Osteoarthritis

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Magnitude of Osteoarthritis disadVantage on pEoples liveS

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Estimate the prevalence of self-reported osteoarthritis (OA) in adults over 45 years of age by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Characterization of self-reported patients with OA by collecting socio-demographic information through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Characterization of self-reported patients with OA by collecting comorbidities information through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Characterization of self-reported patients with OA by collecting information for intensity of pain through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Characterization of OA diagnosis in patients with self-reported OA by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Impact of self-reported OA in the working abilities, quality of life and functionality using Questionnaire SF-12 v2.0 [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Patient perception of impact of OA in its life and importance given to disease by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: Yes ]

Enrollment: 1015
Study Start Date: September 2011
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Detailed Description:

Magnitude of Osteoarthritis disadvantage on peoples lives.

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

- Adults over 45 years old with self-reported osteoarthritis

Exclusion Criteria:

- NA

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01423097

Locations
Portugal
Research Site
Queluz Baixo, Barcarena, Portugal
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01423097     History of Changes
Other Study ID Numbers: NIS-RPO-XXX-2011/2
Study First Received: August 24, 2011
Last Updated: October 9, 2012
Health Authority: Portugal: Data Protection National Committee

Keywords provided by AstraZeneca:
osteoarthritis symptoms

Additional relevant MeSH terms:
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on July 22, 2014